Identifying Co-Exposure to Opiates and Gabapentin During Pregnancy

J Pediatr. 2020 Feb:217:196-198. doi: 10.1016/j.jpeds.2019.09.029. Epub 2019 Oct 24.

Abstract

Neonatal withdrawal can be difficult to treat in infants with co-exposure to opiates and gabapentin. Because maternal self-report can underestimate exposures, we evaluated the effect of universal toxicology screening for gabapentin. Identification of co-exposure to opiates and gabapentin increased after implementation of toxicology screening, with implications for improved neonatal care.

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Excitatory Amino Acid Antagonists / adverse effects
  • Female
  • Follow-Up Studies
  • Gabapentin / adverse effects*
  • Humans
  • Incidence
  • Infant, Newborn
  • Neonatal Abstinence Syndrome / diagnosis
  • Neonatal Abstinence Syndrome / epidemiology
  • Neonatal Abstinence Syndrome / prevention & control*
  • Opiate Alkaloids / adverse effects*
  • Pregnancy
  • Prenatal Exposure Delayed Effects / diagnosis
  • Prenatal Exposure Delayed Effects / epidemiology
  • Prenatal Exposure Delayed Effects / prevention & control*
  • Retrospective Studies
  • West Virginia / epidemiology

Substances

  • Analgesics, Opioid
  • Excitatory Amino Acid Antagonists
  • Opiate Alkaloids
  • Gabapentin